Best Cardiac and Vascular Disorders Companies in San Diego, United States
The 38 best Cardiac and Vascular Disorders companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Acutus Medical.
Ranked: Best Cardiac and Vascular Disorders companies in San Diego
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Acutus Medical Developer of ablation products for the treatment of cardiac arrhythmias | $304M | 86 mo ago | 285 | 2011 | — | Public | 187 patents Cardiac electrophysiology mapping and ablation catheter technologies for heart diagnostics and therapy. | — |
| 2 | Sangart Developing medicines to enhance the perfusion and oxygenation of oxygen deprived tissues through targeted… | $166M | 171 mo ago | — | 1998 | — | Series D | 104 patents Therapeutic hemoglobin-PEG conjugates for controlled oxygen/CO delivery and drug carriers | — |
| 3 | Celladon Telecommunications solutions provider empowering connectivity through innovation and future-ready technology | $117M | 129 mo ago | 56 | 2000 | Krisztina M. Zsebo ex-CEO | Public | 44 patents Cardiac gene therapy using SERCA2a viral vectors and ER‑stress‑targeting quinolines | — |
| 4 | Huya Bioscience International Globalizing China's biopharma innovation, accelerating drug development and maximizing value | $61M | 136 mo ago | 66 | 2004 | Mireille Gillings CEO | Series B | 68 patents HDAC inhibitor plus PD‑1/PD‑L1 cancer immunotherapy combos and sulcardine anti‑arrhythmic agents | — |
| 5 | CeleCor Therapeutics Developer of POC subcutaneous injectable for treating myocardial infarction | $46M | 54 mo ago | 7 | 2017 | Barry Coller Co-Founder | Series A | — | — |
| 6 | REVA Medical Developer of Balloon-expandable and bioresorbable drug-eluting stent | $42M | 49 mo ago | 32 32 → 55 (+72%) | 1998 | — | Public | 205 patents Radiopaque bioresorbable polymer devices for embolic drug delivery and tissue augmentation | — |
| 7 | Vektor Medical Developer of next-generation technology for mapping cardiac arrhythmias | $29M | 31 mo ago | 20 | 2017 | Chris Villongco Co-Founder and CTO | Series A | 166 patents Advanced cardiac electrophysiology mapping, simulation, and automated ablation workflow tools. | — |
| 8 | Access Scientific Vascular access devices and catheters | $21M | 170 mo ago | 26 | 2004 | — | Acqui-Hired | 101 patents Percutaneous medical access devices and valve-integrated catheter systems | — |
| 9 | Tensys Medical Continuous hemodynamic monitoring systems | $20M | 267 mo ago | 3 | 1995 | — | Deadpooled | — | — |
| 10 | Proviso Medical Developer of endovascular devices integrated with Sonic Lumen Tomography for cardiac diseases | $15M | 12 mo ago | 20 | 2014 | S Ryan Founder & CEO | Series A | — | — |
| 11 | Rejuvenate Bio Developer of gene therapies for treating chronic and age-related diseases | $15M | 26 mo ago | 39 | 2018 | Noah Davidsohn Co-Founder & CSO | Series A | — | — |
| 12 | Critical Diagnostics Developer of biomarkers-based tests for cardiovascular diseases diagnostics | $11M | 104 mo ago | 1 | 2004 | Sven Jacobson Co-Founder & Board Member | Series A | 324 patents Patents concentrated in computing, sensing & instrumentation | — |
| 13 | BioVascular Therapeutics for cardiovascular and vascular disease | $11M | 223 mo ago | 4 | 2005 | John Parrish Founder & CEO | Deadpooled | 24 patents Controlled-release drug delivery formulations targeting platelet inhibition and inflammation reduction. | — |
| 14 | Renova Therapeutics Developer of gene therapies for congestive heart failure and type 2 diabetes | $8M | 25 mo ago | 7 | 2009 | Jack Reich Chief Executive Officer | Series C | — | — |
| 15 | Ventrix Developer of extracellular matrix-based therapeutics for cardiac diseases | $6M | 35 mo ago | 2 | 2009 | Karen Christman Co-Founder | Funding Raised | 18 patents Cardiac therapeutic compositions and delivery methods for heart tissue treatment | — |
| 16 | toSense Innovating healthcare with connected solutions, medical devices, and advanced technologies | $5M | 103 mo ago | 8 | 2014 | Bobby Kandaswamy CEO | Acquired | 131 patents Wearable physiological sensors for continuous cardiac and vital sign monitoring | — |
| 17 | Angiocrine Bioscience Therapeutics based on genetically modified endothelial cells | $4M | 12 mo ago | 29 | 2012 | — | Series A | 117 patents Patents concentrated in health & consumer products | — |
| 18 | CardioCell Online slot gaming platform with diverse games and easy jackpots | $1M | 135 mo ago | 6 | 2013 | — | Series A | 4 patents Cell‑based therapies using mesenchymal stem cells for non‑ischemic heart failure | — |
| 19 | ThermopeutiX Provides therapeutics solution for vascular related disorders and others issues | $1M | 255 mo ago | — | 2004 | Ron Solar Founder & CEO | Seed | 48 patents Patents concentrated in health & consumer products | — |
| 20 | Jaan Biotechnology Provider of small molecule miRNA inhibitors for cardiovascular diseases | $839K | 72 mo ago | — | 2015 | Bhawanjit Brar Founder & CEO | Funding Raised | — | — |
| 21 | Gene Biotherapeutics Developer of gene therapeutics for cardiovascular diseases | $750K | 206 mo ago | 3 | 2003 | — | Public | — | — |
| 22 | Theragene Pharmaceuticals Developer of immunotherapy and gene therapy for cardiology and oncology | $548K | 133 mo ago | 3 | 2011 | — | Seed | — | — |
| 23 | Antlia Bioscience Developer of peptide-based therapeutic solutions for the treatment of chronic heart failure | $207K | 23 mo ago | 3 | 2020 | Nigel Shankley Co-Founder | Seed | — | — |
Top 12 Cardiac and Vascular Disorders companies in San Diego
#1
Series A · San Diego, California · founded 2014 · 20 employees$15Mraised▾
Developer of endovascular devices integrated with Sonic Lumen Tomography for cardiac diseases. Its technology platform provides real-time measurements of a vessel’s flow lumen via enabling intravascular ultrasound to be effectively a multidirectional sonar range detector. It produces data without user interaction for low-resolution angiography’s ionizing radiation.
- Aug 2025Series A$3.1M
- Apr 2025Conventional Debt$1.3M
- Jun 2024Series A$5M
- Apr 2024Series A$970K
#2
Series A · San Diego, California · founded 2012 · 29 employees$4Mraised▾
Angiocrine Bioscience develops therapeutics based on genetically modified endothelial cells. Their proprietary E-CEL Technology comprises cultured endothelial cells that have been genetically modified via insertion of the adenovirus E4ORF1 gene. This allows the cells to grow ex-vivo and secrete angiocrines that promote tissue regeneration. The company is currently investigating applications in lung regeneration, sports medicine and immune regeneration in indications such as high-risk hematological malignancies and sickle cell anemia.
- Aug 2025Series A$2.1M
- Mar 2013Series A$4M
#3
Series A · San Diego, California · founded 2018 · 39 employees$14.6Mraised▾
Developer of gene therapies for treating chronic and age-related diseases. The company's pipeline include RJB-0402 (liver-directed FGF21 for metabolic diseases), RJB-01, RJB-02, and RJB-03, with early focus on canine therapies before human translation.
- Jul 2024Grant (prize money)$4M
- Apr 2021Series A$14.6M
#4
Series C · San Diego, California · founded 2009 · 7 employees$7.7Mraised▾
Developer of gene therapies for congestive heart failure and type 2 diabetes. The company’s lead product, RT-100 for congestive heart failure (CHF) is a single-dose treatment designed to safely improve heart function. The second candidate for diabetes, RT-200, delivers a therapeutic gene – urocortin 2 – using a single intravenous injection. The company is also developing RT 400, a peptide therapy for acute decompensated heart failure.
- Jul 2024Series C$166.5K
- Sep 2019Grant (prize money)$1.8M
- Feb 2016Grant (prize money)$1.6M
- Sep 2014Series C$7.5M
#5
Series A · San Diego, California · founded 2017 · 20 employees$28.9Mraised▾
Developer of next-generation technology for mapping cardiac arrhythmias. The company's non-invasive arrhythmia mapping technology vMap uses computational modeling and the patient’s electrocardiogram. It helps in the evaluation, investigation, and treatment of complex cardiac rhythm disorders.
- Feb 2024Series A$28.9M
#6
Public · San Diego, California · founded 2011 · 285 employees$304.4Mraised▾
Developer of ablation products for the treatment of cardiac arrhythmias. It claims to have a medical evidence-based approach to treat atrial fibrillation, ventricular tachycardia, and other arrhythmias. Its product, AcQMap, is a high-resolution imaging and mapping system to overlay dipole density signals on an ultrasound-based reconstruction of the left atrial chamber.
- Jun 2019Series D$100M
- Jun 2019Conventional Debt$70M
- Jun 2018Series C$22.8M
- Mar 2016Series C$75M
#7
Public · San Diego, California · founded 1998 · 32 employees$42Mraised▾
Developer of Balloon-expandable and bioresorbable drug-eluting stents. It works as a scaffold helping in the restoration of blood flow. It supports the artery through the healing process, then gets absorbed over a period of time. The resorption allows the return of natural movement and function of the artery. The initial intended commercial product, the Fantom scaffold, has been designed to offer visibility under x-ray and expansion in one smooth step.
- Aug 2022Post IPO$45M
- Apr 2019Post IPO$3.8M
- Jun 2017Post IPO$34.6M
- Apr 2017Conventional Debt$52.5M
#8
Funding Raised · San Diego, California · founded 2009 · 2 employees$5.7Mraised▾
Developer of extracellular matrix-based therapeutics for cardiac diseases. It offers biomaterial scaffold for endogenous repair and for the repair of damaged myocardium, enabling patients to get tissue engineering products for cardiovascular disease.
- Sep 2023Grant (prize money)$2M
- May 2020Grant (prize money)$791.5K
- Sep 2011Grant (prize money)$496.9K
- Mar 2011Grant (prize money)$2.1M
#9
Series A · San Diego, California · founded 2017 · 7 employees$46.5Mraised▾
Developer of POC subcutaneous injectable for treating myocardial infarction. The therapy used is a platelet mediated thrombosis targeting agent to stop clotting which is the reason for the closing of a coronary artery and causing a heart attack. The company has developed RUC-4 which is a small molecule inhibitor of the platelet GPIIb/IIIa (αIIbβ3) receptor.
- Feb 2022Series A$45.5M
- May 2021Seed$1M
#10
Public · San Diego, California · founded 2000 · 56 employees$117Mraised▾
Telecommunications solutions provider empowering connectivity through innovation and future-ready technology. The company delivers impactful and reliable telecommunications solutions. Specializing in telegraphy, satellite communications, and telephony, it pioneers trends in the telecommunications sector, offering services from mobile connectivity to secure transactions. It provides cutting-edge solutions, including next-generation mobile networks, AI, and IoT, ensuring accessibility and reliability. VoIP solutions redefine traditional telephony, offering cost-effective, scalable, and cloud-based communication for businesses. The company harnesses IoT data for efficiency, innovation, and smarter decision-making. Blockchain technology enhances the safety of every digital interaction. It delivers fixed VoIP telephony and designs reliable connectivity, tailoring each project to meet specific needs. The company is committed to digital success, navigating the future of telecommunications with confidence.
- Nov 2015Post IPO$39.5M
- Oct 2013Conventional Debt$1.1M
- May 2012Series D$19.5M
- Feb 2012Series D$43M
#11
Seed · San Diego, California · founded 2020 · 3 employees$207Kraised▾
Developer of peptide-based therapeutic solutions for the treatment of chronic heart failure. The company is using PASylation synthetic drugs with pharmacologic and pharmacokinetic properties to develop naturally occurring hormones through the development of proprietary peptides. Its technology creates a genetic fusion with polypeptide sequences that are composed of the amino acids Pro, Ala, and Ser.
- Sep 2024Grant (prize money)$1000K
- Oct 2020Seed$207K
#12
Series D · San Diego, California · founded 1998$165.9Mraised▾
Developing medicines to enhance the perfusion and oxygenation of oxygen deprived tissues through targeted oxygen delivery.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.